PE 22-28 preclinical paper, what I think of the fast‑acting antidepressant claim

Posted by ivy_mobility in Research & News - 1 points, 0 comments.

com/peptides/pe-22-28). The authors show that blocking TREK-1 with this spadin‑derived peptide leads to rapid antidepressant‑like effects in animal models, plus increased neurogenesis and synaptogenesis. It’s interesting because the mechanism lines up with what we see from other fast‑acting compounds that boost serotonergic signaling, but the human data is still nowhere near existent.

For me the appeal is the potential to add something short‑acting to a stack without the long half‑life of classic psychedelics, yet I’m cautious about jumping in without any safety track record. I’ve been tracking my HRV and sleep on a few nootropic experiments and nothing has moved the needle as dramatically as the paper suggests for rodents.

Community discussion - research and educational context only. Not medical advice.